CNV patients are responsive when switching anti-VEGF therapies

Article

Choroidial neovascularisation (CNV) patients are responsive when switching to bevacizumab or ranibizumab after they develop tachyphylaxis during anti-vascular endothelial growth factor (VEGF) therapy.

Choroidial neovascularisation (CNV) patients are responsive when switching to bevacizumab or ranibizumab after they develop tachyphylaxis during anti-vascular endothelial growth factor (VEGF) therapy, states a study in the British Journal of Ophthalmology.

A team led by Dr Srinivas Sadda, Doheny Eye Institute, Los Angleles, California, USA, included 26 eyes in the retrospective investigation. The records of CNV patients that were administered both bevacizumab and ranibizumab were reviewed to determine which patients had developed tachyphylaxis during treatment.

Tachyphylaxis was identified as OCT evidence of reduced exudation. Subretinal fluid (SRF), pigment epithelial detachment (PED) and cystoid macular oedema (CMO) were used to determine signs of exudation.

Of the 26 eyes featured in the study, 10 were treated with bevacizumab and then switched to ranibizumab in order to treat SRF, PED and CMO. Seven had occult CNV and three had predominantly classic CNV. There was no response in 1 eye of the occult CNV group after switching to ranibizumab treatment and there was a positive therapeutic response.

The remaining 16 eyes underwent ranibizumab treatment and then switched to bavacizumab. In this group there were 15 eyes with occult CNV and 1 with predominantly classic CNV. Of these eyes, 2 responded to ranibizumab treatment and 1 was unresponsive. Bevacizumab treatment caused 6 eyes to improve after one injection and 5 eyes to improve after 2 injections. The remaining 16 failed to respond.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.